RIGI and neoplasm: Knocking out Rig-I in CD8+ T cells from OT-1 mice and coculturing them with MC38-OVA cells at different target-effector ratios revealed that the absence of Rig-I enhanced the specific killing of tumour cells by CD8+ T cells (Fig. 4A).